RxDoctor Payments Data

Lydia Issac, MD

Cardiovascular Disease · Chicago, ILNPI 1679953954

Payments from drug & device makers

$1,747in general payments, 2019–2025

Across 40 payments — averaging $43.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$327
  • Convatec Inc.$318
  • Astellas Pharma US Inc$290
  • Novartis$185
  • AstraZeneca$170
  • Chiesi USA, Inc.$150
  • plus $307 from 8 others

What the payments were for

  • Food & beverage$1,45783%
  • Education$29017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,747 in reported general payments places this provider in the 50th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$101,122
Medicare patients
796
Services billed
1,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$103,714
EntrestoSacubitril/Valsartan48$49,467
JardianceEmpagliflozin20$26,954
XareltoRivaroxaban24$20,317
FarxigaDapagliflozin Propanediol26$19,439
BrilintaTicagrelor11$9,954
Metoprolol Succinate188$3,331
Atorvastatin Calcium271$2,416
Valsartan67$1,597
Nifedipine ErNifedipine41$1,136
Carvedilol121$865
Amlodipine Besylate151$785
Ezetimibe28$699
Rosuvastatin Calcium40$687
Albuterol Sulfate HfaAlbuterol Sulfate18$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$185$49,46748 claims
AstraZenecaFarxiga, Brilinta$170$29,39437 claims
Boehringer IngelheimJardiance$39$26,95420 claims
Johnson & JohnsonXarelto$112$20,31724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →